ResearcherPeking UniversityActive in the last 2 years
Mo Chen
Matched on ORCID iD 0000-0002-6647-8483; OpenAlex author ID A5100387252. Sources: OpenAlex.
Their work
- Papers
- 6 (first author 0, last author 2)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 21
2021: 1 paper · 2022: none · 2023: none · 2024: none · 2025: 4 papers · 2026: 1 paper
Papers 6
- A conserved re-epithelialization program underlies malignancy in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.ccell.2026.03.021↗
- DR1 activates histone gene expression to maintain pancreatic cancer cell survival through the ATAC complex. Last author DOI 10.1038/s41417-025-00938-0↗
- STN1 facilitates metastasis by promoting transcription of EMT-activator ZEB1 in pancreatic cancer. Co-author DOI 10.1038/s41467-025-63083-0↗
- Targeting TUT1 Depletes Tri-snRNP Pools to Suppress Splicing and Inhibit Pancreatic Cancer Cell Survival. Last author DOI 10.1158/0008-5472.can-24-2563↗
- Targeting plasticity in the pyrimidine synthesis pathway potentiates macrophage-mediated phagocytosis in pancreatic cancer models. Co-author DOI 10.1172/jci193370↗
- Mutant Kras co-opts a proto-oncogenic enhancer network in inflammation-induced metaplastic progenitor cells to initiate pancreatic cancer. Co-author DOI 10.1038/s43018-020-00134-z↗
Closest collaborators
The 21 strongest of 21 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Charles J. David · 3 shared papers, 2021–2026 · strength 0.61
- Paper Targeting TUT1 Depletes Tri-snRNP Pools to Suppress Splicing and Inhibit Pancreatic Cancer Cell Survival. DOI 10.1158/0008-5472.can-24-2563↗
- Paper A conserved re-epithelialization program underlies malignancy in pancreatic ductal adenocarcinoma. DOI 10.1016/j.ccell.2026.03.021↗
- Paper Mutant Kras co-opts a proto-oncogenic enhancer network in inflammation-induced metaplastic progenitor cells to initiate… DOI 10.1038/s43018-020-00134-z↗
- Ziwei Guo · 2 shared papers, 2025 · strength 0.53
- Ziwei Guo · 1 shared paper, 2025 · strength 0.42
- Meilian Zhuo · 2 shared papers, 2021–2026 · strength 0.30
- Junya Peng · 2 shared papers, 2021–2026 · strength 0.30
- Yupei Zhao · 2 shared papers, 2021–2026 · strength 0.30
- Jingjing Gong · 1 shared paper, 2025 · strength 0.25
- Di Dong · 1 shared paper, 2025 · strength 0.25
- Yuxin Yin · 1 shared paper, 2025 · strength 0.25
- Deng Pan · 1 shared paper, 2025 · strength 0.22
- Jie Zhao · 1 shared paper, 2025 · strength 0.22
- Xianlin Han · 1 shared paper, 2026 · strength 0.21
- Ruizhe He · 1 shared paper, 2026 · strength 0.21
- Mingyang Liu · 1 shared paper, 2026 · strength 0.21
- Menghua Dai · 1 shared paper, 2026 · strength 0.21
- Weibin Wang · 1 shared paper, 2026 · strength 0.21
- Yong Li · 1 shared paper, 2021 · strength 0.10
- Xun Lan · 1 shared paper, 2021 · strength 0.10
- Wenze Wang · 1 shared paper, 2021 · strength 0.10
- Wenming Wu · 1 shared paper, 2021 · strength 0.10
- Jing Xue · 1 shared paper, 2021 · strength 0.10
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.